Specialties

Post-hoc analysis of 3 large trials maps sex differences in PsA

Presented By

Dr Laura Coates, University of Oxford, UK

Trial

DISCOVER-1, DISCOVER-2, COSMOS

Conference

ACR 2024

Type

News article

19 November 2024 11:25

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

IL-22RA1 inhibition shows potential in atopic dermatitis

Presented By

Dr Christine Bangert, Medical University Vienna, Austria

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:56

Lifelong psychosocial burden linked to early-onset atopic dermatitis

Editor

George Washington University School of Medicine, USA

Trial

Scars of Life

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:53

Second-generation selective PDE4 inhibitor shows promise in AD

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA)

Trial

Phase 2, ADESOS

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:50

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

DELTA; LIBERTY-AD-HAFT

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:30

Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

Presented By

Prof. Adam Reich, University of Rzeszów, Poland

Trial

Phase 3, GEMINI-1; GEMINI-2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:04

A new era of care: Artificial intelligence in psoriasis

Presented By

Prof. Alexander Navarini, University Hospital of Basel, Switzerland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:00

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Small protein targeting IL-17A effective in PsA management

Presented By

Prof. Philip Mease, University of Washington; Swedish Medical Center, WA, USA

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease

Presented By

Dr Jeffrey Sparks, Brigham and Women's Hospital, MA, USA

Trial

RheumCARD

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:29

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

Genetic and immunological advances in risk assessment and treatment of psoriatic diseases

Presented By

Prof. Wilson Liao, University of California San Francisco, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:32

Using advances in the genetics of psoriatic disease to better predict treatment response

Presented By

Prof. Carl Goodyear, University of Glasgow, Scotland

Conference

IFPA 2024

Type

News article

17 July 2024 14:28

Depression complicates the management of psoriatic disease

Presented By

Dr Wiebke Sondermann, University Hospital Essen, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:20

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Managing obesity and fibromyalgia in psoriatic disease

Presented By

Prof. Philip Mease, University of Washington, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:08

Multiple novel oral agents show promise in psoriasis

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

FRONTIER; STRIDE

Conference

IFPA 2024

17 July 2024 14:04

Biologics for psoriasis: towards oral therapies and less frequent dosing

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Trial

LIMMItless; GUIDE; FRONTIER

Conference

IFPA 2023

Type

News article

17 July 2024 14:00

Advances in psoriasis treatment: topical therapies show promising results

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

PSOARING; DERMIS

Conference

IFPA 2024

Type

News article

17 July 2024 13:49

Improving outcomes in pregnancy and psoriatic disease

Presented By

Dr Oseme Etomi, Guy's and St Thomas' Hospital, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:44

Towards prevention of psoriatic arthritis in patients with psoriasis

Presented By

Prof. Laura Coates, University of Oxford, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:39

Diagnosing generalised pustular psoriasis

Presented By

Dr Siew Eng Choon, Monash University Malaysia

Conference

IFPA 2024

Type

News article

17 July 2024 13:37

Itch and pain are major components of psoriatic disease and require management

Presented By

Prof. Adam Reich; Dr Anushka Irani

Conference

IFPA 2024

Type

News article

17 July 2024 12:07

Can diet help with the management of psoriasis?

Presented By

Prof. Wendy Hall, King's College London, UK

Trial

APPLE; METRED-P

Conference

IFPA 2024

Type

News article

17 July 2024 12:00

Biologics in psoriatic arthritis: where we are and where we are headed

Presented By

Dr Vinod Chandran

Conference

IFPA 2024

Type

News article

17 July 2024 11:55

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Improving risk classification in cutaneous squamous cell carcinoma

Presented By

Dr Marlies Wakkee, Erasmus MC Rotterdam, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:54

Ins and outs of tumour-infiltrating lymphocytes therapy in metastatic melanoma

Presented By

Dr Tom Seijkens, Netherlands Cancer Institute, the Netherlands

Conference

DDD 2024

31 May 2024 12:40

Children with atopic dermatitis may be smaller and heavier than healthy children

Presented By

Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA

Trial

PEDISTAD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:54

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

Robust long-term efficacy of bimekizumab in psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

BE BRIGHT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:09

Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 2, STRIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Amlitelimab leads to a high response 28 weeks after treatment discontinuation

Presented By

Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany

Trial

Phase 2, STREAM-AD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:35

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:06

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial

Expert

Dr Andrew Blauvelt

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

22 April 2024 12:12

Lifileucel induces a durable response in heavily pretreated mucosal melanoma

Presented By

Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA

Trial

Phase 2, C-144-01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:15

Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma

Presented By

Dr Meridith McKean, Tennessee Oncology, USA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:06

Ixekizumab resolves nail psoriasis better than adalimumab in PsA

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 4, SPIRIT-H2H

Conference

ACR 2023

Type

News article

1 December 2023 12:36

IV secukinumab safe and effective for long-term treatment of active PsA

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

FUTURE 2-5

Conference

ACR 2023

Type

News article

1 December 2023 12:04

Apremilast in early oligoarticular PsA: phase 4 study results

Presented By

Dr Philip Mease, University of Washington, WS, USA

Trial

Phase 4, FOREMOST

Conference

ACR 2023

Type

News article

1 December 2023 12:03

Tapinarof on course to become a new topical treatment in AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ADORING

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:43

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

IL-13 inhibitor shows potential in atopic dermatitis

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 2, TREK-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:08

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:50

Improved AI tool shows high sensitivity rates in skin cancer detection

Presented By

Dr Kashini Andrew, University Hospitals Birmingham NHS Foundation Trust, UK

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:46

Dermoscopy training combined with AI significantly improves skin cancer detection

Presented By

Dr Christian Dorado Cortez, University Hospital of Saint-Etienne, France

Conference

EADV 2024

Type

Peer-reviewed article

28 November 2023 09:43

Analysing the Link Between Psoriasis and Chronic Kidney Disease

20 October 2023 12:20

Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings

Trial

Review study, GRAPPA

20 October 2023 12:15

Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients

Presented By

Dr Maria Rita Lo Monaco, Catholic University of the Sacred Heart, Italy

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:27

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

Vascular inflammation may be characteristic of PsA

Presented By

Dr Nienke Kleinrensink, UMC Utrecht, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:18

Obesity in PsA is increasingly affecting male patients

Presented By

Dr Marlene Stirnimann-Agustoni, University Hospital of Zürich, Switzerland

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:13

PsA patients: highest risk of developing NAFLD

Presented By

Mr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:09

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:58

Eligibility and selection of JAK inhibitors for constitutional eczema

Presented By

Dr Dirk Jan Hijnen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:57

The role of surgeons in stage I–II melanoma

Presented By

Dr Dirk Grünhagen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:26

Melanoma: Surveillance and follow-up

Presented By

Dr Remco van Doorn, Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:19

OCT non-inferior to biopsy in basal cell carcinoma

Presented By

Dr Tom Wolswijk , Maastricht UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 12:42

Bimekizumab: Robust 1-year results in treating psoriatic arthritis

Presented By

Prof. Christopher Ritchlin, University of Rochester Medical Center, USA

Trial

Phase 3

Conference

ACR 2022

Type

News article

1 December 2022 14:33

Tralokinumab improves symptoms and quality of life in adolescents with moderate-to-severe AD

22 November 2022 17:09

Patients & physicians have discordant views of atopic dermatitis symptoms

18 November 2022 11:45

Type 2 inflammatory diseases in paediatric patients with atopic dermatitis

18 November 2022 10:37

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By

Prof. John Haanen, Netherlands Cancer Institute, the Netherlands

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:29

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas

Presented By

Dr Sapna Patel, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, SWOG S1808

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:26

Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up

Presented By

Prof. Reinhard Dummer, University of Zürich, Switzerland

Trial

T-VEC

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:24

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate 915

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:21

Genital psoriasis: high prevalence, often underdiagnosed

Presented By

Dr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:12

Markedly lower skin cancer risk in vitiligo patients

Presented By

Dr John Ferguson, St John’s Institute of Dermatology, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:47

Novel oral psoriasis drug maintains efficacy over 2 years

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK-PSO-1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:36

A3 adenosine receptor agonist showed modest efficacy but excellent tolerability

Presented By

Dr Kim A. Papp, Probity Medical Research, Canada

Trial

Phase 3, COMFORT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:32

Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

KEEPsAKE 1; KEEPsAKE 2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:28

AI machine learning algorithm useful in early detection of PsA

Presented By

Dr Jonathan Shapiro, Maccabi Healthcare Services, Israel

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:24

Baricitinib possible therapeutic option for children with AD

Presented By

Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain

Trial

Phase 3, BREEZE-AD-PEDS

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:15

Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients

Presented By

Dr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:10